Pharmacotherapy in bronchopulmonary dysplasia

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants.
• Effective management of BPD requires a multifaceted pharmacological approach.
• Current treatment strategies involve various drug classes to address respiratory and associated complications.

Purpose of the Study:

• To review the most frequently used drugs in the management of bronchopulmonary dysplasia.
• To summarize the known advantages, side effects, and current dosages of these medications.
• To provide an evidence-based overview for clinicians treating BPD.

Main Methods:

• Literature review of current data on BPD pharmacotherapy.
• Analysis of drug efficacy, safety profiles, and dosing guidelines.
• Synthesis of information on oxygen, diuretics, bronchodilators, steroids, ribavirin, and antioxidants.

Main Results:

• Oxygen therapy remains a cornerstone for BPD management.
• Diuretics, bronchodilators, and steroids are frequently employed, each with specific indications and risks.
• Antioxidants and antiviral agents like ribavirin show potential but require further investigation.
• Medications for co-existing conditions like pulmonary hypertension, systemic hypertension, and gastroesophageal reflux are also critical.

Conclusions:

• Optimal BPD pharmacotherapy involves careful selection and titration of multiple agents.
• Understanding the risk-benefit profile of each drug is essential for individualized patient care.
• Ongoing research is crucial for refining treatment protocols and improving long-term outcomes in BPD survivors.